Aggregate Safety Reporting in Pharmacovigilance: PSUR, PBRER, DSUR and PADER Explained

Introduction

Aggregate safety reporting is an essential activity in pharmacovigilance that helps regulators and pharmaceutical companies monitor the safety of medicines throughout their lifecycle. Unlike Individual Case Safety Reports (ICSRs), which describe single adverse event cases, aggregate safety reports analyze cumulative safety data collected over a defined reporting period.

These reports allow experts to detect safety trends, identify potential risks, and evaluate whether the overall benefit–risk balance of a medicine has changed over time. Regulatory authorities worldwide require the routine submission of aggregate safety reports to ensure continuous drug safety monitoring.

What Is Aggregate Safety Reporting in Pharmacovigilance?

Aggregate safety reporting is the cumulative analysis of serious and non-serious adverse events collected over a defined reporting period, in accordance with country-specific regulatory requirements, called as aggregate reporting in pharmacovigilance.
Unlike Individual Case Safety Reports (ICSRs), which look at one adverse event at a time, aggregate reports combine data from

• serious and non-serious side effects
• clinical trials and
• real-world use after the medicine is on the market.

These reports are prepared according to country-specific rules and timelines. The goal is to give a complete picture of a medicine’s safety over time. By looking at trends, patterns, and the overall benefit–risk balance

Why Is Aggregate Safety Reporting Important?

Aggregate safety reports help to:

• Detect emerging safety signals

• Monitor long-term drug safety trends

• Evaluate benefit–risk balance

• Support regulatory decision-making

• Ensure compliance with global pharmacovigilance regulations

Aggregate safety analysis is closely related to signal detection, which identifies potential safety concerns from large datasets. Learn more in our article on Signal Detection in Pharmacovigilance.

Aggregate reports are critical because they:

Types of Aggregate Safety Reports

There are several types of aggregate reports, depending on the stage of the product and the region:

Report	Stage	Region	Frequency
PADER	Post-marketing	USA	Quarterly / Annual
PBRER	Post-marketing	Global	6 months / yearly
PSUR	Post-marketing	Global (older format)	6 months / yearly
DSUR	Clinical development	Global	Annual
ASUR	Regional requirement	Some countries	Annual

Aggregate reports follow regulatory timelines and reporting requirements defined by international guidelines. Learn more in our article on Pharmacovigilance Regulatory Timelines.

PADER (Periodic Adverse Drug Experience Report – USA, FDA)

The PADER is an aggregate safety report required by the US Food and Drug Administration (FDA) to evaluate the ongoing safety of marketed drugs in the United States. Its main purpose is to allow the FDA to continuously monitor adverse drug experiences and identify any new or changing safety concerns after a product has been approved.

Applicable Products

• FDA-approved marketed drugs
• Products approved under NDA (New Drug Application) or ANDA (Abbreviated NDA)
• Excludes investigational products unless specified

Submission Frequency

• Quarterly PADERs: Submitted during the first 3 years after FDA approval
• Annual PADERs: Submitted after the initial 3-year period

• Reports are aligned with the product’s US approval anniversary date

Regulatory Reference

• 21 CFR 314.80(c)(2): This regulation defines FDA requirements for post-marketing adverse drug experience reporting, including periodic aggregate submissions.

PBRER(Periodic Benefit–Risk Evaluation Report)

Focus on Benefit–Risk Balance

The Periodic Benefit–Risk Evaluation Report (PBRER) is a global regulatory report required after a medicine is approved and available in the market. Its main purpose is to regularly check whether the benefits of a medicine continue to outweigh its risks as more patients use it in real-world settings.

Unlike older reports that mainly focused on side effects, the PBRER looks at the complete picture, including:

• Safety data (side effects and risks)
• Effectiveness of the medicine
• Risk minimization measures (warnings, precautions, monitoring)
• Real-world experience after marketing approval

Submission Frequency

• Every 6 months for the first 2 years after initial marketing authorization
• Annually for the next 3 years
• Thereafter: At intervals defined by regulatory authorities (often longer cycles or on request)

Regulatory Guideline

👉ICH E2C(R2) – Periodic Benefit–Risk Evaluation Report

This guideline defines the format, content, and purpose of the PBRER globally.

What Is the Main Purpose of a PBRER?

Once a medicine is approved, it is used by a wide variety of patients—different ages, health conditions, and backgrounds. Because of this broader use, new safety or effectiveness information may appear over time.

The PBRER is prepared to:

• Review new safety information collected during a fixed reporting period
• Confirm that the medicine is still effective in real-world use
• Evaluate benefits and risks together, not separately

The ultimate goal is to ensure that the medicine remains safe and useful for patients.

Why Did PSUR Change to PBRER?

Earlier reports called PSURs (Periodic Safety Update Reports) mainly focused on safety problems.

Regulators later recognized that:

• Safety alone does not give the full picture
• Risks must always be judged alongside benefits

Example:

• Serious side effects may be acceptable for a life-saving cancer drug
• The same side effects may not be acceptable for a mild painkiller

Because of this, PSURs evolved into PBRERs, which focus on the overall benefit–risk balance, not just side effects.

Why Is the PBRER Important?

The PBRER ensures that drug safety monitoring continues throughout the medicine’s lifecycle, not just at the time of approval.

It helps to:

• Detect safety issues early
• Protect patient health
• Support regulatory decision-making
• Ensure responsible use of medicines worldwide

In short, the PBRER makes medicine safety a continuous and proactive process, not a one-time check.

DSUR (Development Safety Update Report – Global, ICH)

Focus on Safety During Clinical Development

The Development Safety Update Report (DSUR) is a globally harmonized annual safety report required while a medicine is still in the clinical development phase. 

Its main purpose is to regularly review and evaluate safety data to ensure the continued protection of clinical trial subjects.

Unlike post-marketing reports, the DSUR focuses only on medicines that are not yet fully approved and are being studied in clinical trials.

What Does the DSUR Focus On?

The DSUR provides a complete and cumulative review of safety data collected from:

• Clinical trial adverse events
• Serious adverse reactions
• Non-clinical (animal and laboratory) safety findings
• Safety data from other relevant sources

Its goal is to identify new or changing risks and determine whether the ongoing clinical trials remain safe to continue.

Submission Frequency

• Submitted annually
  
• The reporting period is based on the Development International Birth Date (DIBD)
  
• Must be submitted within 60 calendar days after the Data Lock Point (DLP)

Regulatory Guideline

👉ICH E2F – Development Safety Update Report
This guideline defines the structure, content, and global requirements for DSUR submission.

What Is the Main Purpose of a DSUR?

During clinical development, patient exposure is limited and controlled. However, safety information continues to evolve as more subjects are enrolled.
The DSUR is prepared to:

• Review all new safety information collected over the past year
• Compare new findings with what was previously known
• Identify risks that may impact trial subjects
• Support decisions on whether study protocols need changes

The ultimate aim is to protect participants enrolled in clinical trials.

Why Is the DSUR Important?

The DSUR ensures that safety monitoring is continuous and proactive, not reactive.
It helps to:

• Detect emerging safety concerns early
• Ensure ethical conduct of clinical trials
• Support regulatory oversight
• Maintain patient safety throughout drug development

In short, the DSUR ensures that a medicine is safe enough to continue testing in humans.

ASUR (Annual Safety Update Report – Region-Specific)

Focus on Annual Safety Monitoring

The Annual Safety Update Report (ASUR) is an annual safety summary required by some national regulatory authorities. It provides an overview of the safety profile of a medicinal product over a defined reporting period.

The ASUR is mainly used in regions where PSUR or PBRER is not mandatory or where local regulations require an annual safety update.

What Does the ASUR Focus On?

The ASUR primarily focuses on:

• Reported adverse events
• Serious adverse reactions
• Any significant changes in the safety profile

Its purpose is to ensure that regulators receive regular safety updates for products under their jurisdiction.

Submission Frequency

• Submitted annually
  
• Timeline and format depend on local regulatory requirements

Regulatory Guideline

• Governed by national regulatory authority guidelines
  
• Not harmonized under a single ICH guideline

What Is the Main Purpose of an ASUR?

The ASUR is prepared to:

• Summarize safety data collected over one year
• Identify any new safety concerns
• Confirm that the product’s safety profile remains acceptable

It acts as a routine safety check to support ongoing regulatory monitoring.

Why Is the ASUR Important?

The ASUR helps ensure:

• Continued safety oversight
• Compliance with local regulatory expectations
• Early identification of potential safety risks

In short, the ASUR supports annual safety surveillance where global reports are not required.

PSUR (Periodic Safety Update Report – Global, ICH)

Focus on Safety After Marketing Approval

The Periodic Safety Update Report (PSUR) is an aggregate safety report prepared after a medicine is approved and marketed. Its primary focus is on adverse events and safety risks identified during real-world use.

PSURs were the standard global safety reports before the introduction of PBRERs.

What Does the PSUR Focus On?
The PSUR mainly includes:

• Adverse drug reactions
• Serious adverse events
• Post-marketing safety data
• Cumulative safety experience

It focuses on identifying risks, not on evaluating benefits.

Submission Frequency

• Every 6 months for the first 2 years after approval
• Annually for the next 3 years
• Frequency may vary by region. 

Regulatory Guideline

👉ICH E2C (Original guideline)
This guideline defined the PSUR structure before it was updated to PBRER.

What Is the Main Purpose of a PSUR?

Once a medicine is widely used, rare or long-term adverse effects may appear.

• The PSUR is prepared to:
• Review cumulative safety data
• Identify new or changing safety risks
• Support regulatory action if needed

Its focus is on safety monitoring only, without assessing effectiveness.

Why Did PSUR Evolve Into PBRER?

Regulators recognized that:

• Safety alone does not provide the full picture
• Risks must always be evaluated alongside benefits

As a result, PSURs were replaced by PBRERs, which assess the overall benefit–risk balance.

Why Is the PSUR Important?

The PSUR played a crucial role in:

• Strengthening post-marketing safety surveillance
• Detecting rare adverse reactions
• Laying the foundation for modern benefit–risk evaluation

In short, the PSUR was the starting point of structured post-marketing safety reporting.

The comparison table among the types of Aggregate Reports 

Frequently Asked Questions (FAQs)

1. What is aggregate safety reporting in pharmacovigilance?

Aggregate safety reporting is the cumulative evaluation of adverse event data collected over a defined time period to monitor drug safety.

2. What is the difference between ICSR and aggregate reports?

An ICSR describes a single adverse event case, while aggregate reports analyze multiple cases together to detect trends.

3. What are common aggregate safety reports?

Common reports include PSUR, PBRER, DSUR, PADER and ASUR.

Conclusion:

Aggregate safety reporting is a cornerstone of pharmacovigilance that ensures medicines remain safe throughout their lifecycle. By reviewing cumulative safety data through reports such as PADER, PBRER, PSUR, DSUR, and ASUR, regulators and pharmaceutical companies can detect emerging risks and reassess the benefit–risk balance of medicines.

These reports support regulatory decision-making, protect patient safety, and strengthen global drug safety monitoring systems.

"Stay connected for more simple explanations on pharmacovigilance and regulatory reporting."